Nurit Gal-Mark

Nurit Gal-Mark

Auto-generated profile, based on publicly available information

Nurit Gal-Mark

Schneider Children's Medical Center 2 Petach Tikva

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Purpose: Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework enabling universal molecular surveillance of high-risk neuroblastoma. Experimental Design: Using whole-genome Oxford Nanopore Technologies sequencing of high-risk neuroblastoma tumors, we compared tumor-derived methylation profiles to a comprehensive atlas of normal human cell types and identified 72 neuroblastoma-specific differentially methylated regions (meNBLs) that were reliably detectable in cfDNA. Marker robustness and specificity were validated using independent neuroblastoma methylation datasets and assessed against methylation profiles from other cancer types. We established neuroblastoma as a distinct methylation entity within the reference atlas by integrating a panel of 25 meNBLs, enabling quantitative estimation of tumor-derived cfDNA. Assay performance was evaluated across diagnostic, remission, relapse, and healthy control samples and compared with mutation- and copy number–based approaches. Results: Neuroblastoma-derived cfDNA was consistently detected at diagnosis and relapse, but was absent in healthy controls and during confirmed remission. Methylation-based deconvolution demonstrated high specificity, with no detectable background signal in controls, and improved performance relative to copy number–based tumor fraction estimation. Longitudinal profiling enabled early molecular detection of relapse and reliable disease monitoring. Conclusions: We establish a robust, mutation-independent methylation-based liquid biopsy strategy for neuroblastoma that enables accurate, quantitative disease monitoring across all high-risk patients including those lacking trackable genomic alterations. This approach supports clinical translation of methylation-based cfDNA deconvolution as a broadly applicable platform for pediatric precision oncology.

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S2: Characteristics of cfDNA samples from neuroblastoma patients at diagnosis and controls analyzed by ONT sequencing

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S11: Comparison of ichorCNA performance with provided vs generated panel of normal

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Figure S2: Gene Ontology (GO) enrichment analysis of 152 identified DMRs. The x-axis represents the gene ratio (the proportion of genes from the methylated gene list involved in each GO term), while the size of the dots corresponds to the number of genes associated with each process. The color gradient indicates the adjusted p-value (−log10 p.adjust), reflecting the statistical significance of enrichment.

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Figure S1: Identification of neuroblastoma-specific DMRs through comparative methylome analysis to normal human cell-type atlas. Total of 152 neuroblastoma DMRs were identified in comparison to all tissue types in the human reference atlas (13). Given that neuroblastoma arises from neural crest cells, the analysis was repeated with neuronal cell types excluded from the atlas resulting in the identification of additional 36 “neuronal” regions.

15 September 2026
Verified
Other
Open access
NGNurit Gal-Mark
Nurit Gal-Mark
AGAssaf Grunwald
Assaf Grunwald
VGValid Gahramanov
Valid Gahramanov
MHMichal Hameiri-Grossman
Michal Hameiri-Grossman
ESElena Shinderman-Maman
Elena Shinderman-Maman
EBEsther R. Berko
Esther R. Berko
Supplementary Table S9: List of neuroblastoma-specific DMRs for cfDNA deconvolution analysis